RU2730552C2 - Спироконденсированные пирролидиновые производные в качестве ингибиторов деубиквитилирующих ферментов (DUB) - Google Patents

Спироконденсированные пирролидиновые производные в качестве ингибиторов деубиквитилирующих ферментов (DUB) Download PDF

Info

Publication number
RU2730552C2
RU2730552C2 RU2018133279A RU2018133279A RU2730552C2 RU 2730552 C2 RU2730552 C2 RU 2730552C2 RU 2018133279 A RU2018133279 A RU 2018133279A RU 2018133279 A RU2018133279 A RU 2018133279A RU 2730552 C2 RU2730552 C2 RU 2730552C2
Authority
RU
Russia
Prior art keywords
oxo
pyrrolidine
carbonitrile
dihydro
spiro
Prior art date
Application number
RU2018133279A
Other languages
English (en)
Russian (ru)
Other versions
RU2018133279A (ru
RU2018133279A3 (cg-RX-API-DMAC7.html
Inventor
Марк Иэн КЕМП
Мартин Ли СТОКЛИ
Майкл Дэвид Вудроу
Элисон ДЖОНС
Original Assignee
Мишн Терапьютикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мишн Терапьютикс Лимитед filed Critical Мишн Терапьютикс Лимитед
Publication of RU2018133279A publication Critical patent/RU2018133279A/ru
Publication of RU2018133279A3 publication Critical patent/RU2018133279A3/ru
Application granted granted Critical
Publication of RU2730552C2 publication Critical patent/RU2730552C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2018133279A 2016-03-04 2017-03-02 Спироконденсированные пирролидиновые производные в качестве ингибиторов деубиквитилирующих ферментов (DUB) RU2730552C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1603779.8 2016-03-04
GBGB1603779.8A GB201603779D0 (en) 2016-03-04 2016-03-04 Novel compounds
PCT/GB2017/050565 WO2017149313A1 (en) 2016-03-04 2017-03-02 Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors

Publications (3)

Publication Number Publication Date
RU2018133279A RU2018133279A (ru) 2020-04-06
RU2018133279A3 RU2018133279A3 (cg-RX-API-DMAC7.html) 2020-04-06
RU2730552C2 true RU2730552C2 (ru) 2020-08-24

Family

ID=55859019

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018133279A RU2730552C2 (ru) 2016-03-04 2017-03-02 Спироконденсированные пирролидиновые производные в качестве ингибиторов деубиквитилирующих ферментов (DUB)

Country Status (19)

Country Link
US (3) US10654853B2 (cg-RX-API-DMAC7.html)
EP (2) EP4067355A1 (cg-RX-API-DMAC7.html)
JP (2) JP6959247B2 (cg-RX-API-DMAC7.html)
KR (1) KR102384139B1 (cg-RX-API-DMAC7.html)
CN (1) CN108602823B (cg-RX-API-DMAC7.html)
AU (1) AU2017225371B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018017086B1 (cg-RX-API-DMAC7.html)
CA (1) CA3016370C (cg-RX-API-DMAC7.html)
CO (1) CO2018009275A2 (cg-RX-API-DMAC7.html)
ES (1) ES2919549T3 (cg-RX-API-DMAC7.html)
GB (1) GB201603779D0 (cg-RX-API-DMAC7.html)
IL (1) IL261552B (cg-RX-API-DMAC7.html)
MA (1) MA43701A (cg-RX-API-DMAC7.html)
MX (1) MX382562B (cg-RX-API-DMAC7.html)
MY (1) MY196836A (cg-RX-API-DMAC7.html)
RU (1) RU2730552C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201807301SA (cg-RX-API-DMAC7.html)
WO (1) WO2017149313A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201803910B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3277677T (lt) 2015-03-30 2021-05-25 Mission Therapeutics Limited 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai
EP3322702B1 (en) 2015-07-14 2019-11-20 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) * 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
MA43753A (fr) 2016-03-24 2018-11-28 Mission Therapeutics Ltd Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
ES2850349T3 (es) 2016-09-27 2021-08-27 Mission Therapeutics Ltd Derivados de cianopirrolidina con actividad como inhibidores de USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
JP7208931B2 (ja) 2017-06-20 2023-01-19 ミッション セラピューティクス リミティド Dub阻害剤としての活性をもつ置換シアノピロリジン類
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors
EP3837262B1 (en) 2018-08-14 2026-06-17 Amgen Inc. N-cyano-7-azanorbornane derivatives and uses thereof
EP4218934B1 (en) 2018-10-05 2025-06-18 Forma Therapeutics, Inc. Inhibiting ubiquitin-specific protease 30 (usp30)
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
MX2022012578A (es) 2020-04-08 2022-11-07 Mission Therapeutics Ltd N-cianopirrolidinas con actividad como inhibidores de usp30.
KR20230016674A (ko) 2020-05-28 2023-02-02 미션 테라퓨틱스 엘티디 미토콘드리아 기능장애의 치료를 위한 usp30 억제제로서 n-(1-시아노피롤리딘-3-일)-5-(3-(트라이플루오로메틸)페닐)옥사졸-2-카복스아미드 유도체 및 상응하는 옥사다이아졸 유도체
WO2021245186A1 (en) 2020-06-04 2021-12-09 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
RS67140B1 (sr) 2020-06-08 2025-09-30 Mission Therapeutics Ltd 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primenu u lečenju mitohondrijske disfunkcije, kancera i fibroze
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
CN116143782B (zh) * 2021-11-22 2024-04-12 西南大学 一类螺[吡咯烷-2,3'-喹啉]-2'-酮类衍生物的设计合成与应用
WO2023099561A1 (en) 2021-12-01 2023-06-08 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
JP2025500506A (ja) * 2021-12-23 2025-01-09 ザ・カトリック・ユニヴェルシテイト・ルーバン Yap/taz-teadを阻害するためのスピロ及び関連類似体
WO2024151847A1 (en) * 2023-01-13 2024-07-18 The University Of North Carolina At Chapel Hill Identification of otud7b inhibitor 7bi and its application in reducing growth of nsclc and leukemia cells
GB202408928D0 (en) 2024-06-21 2024-08-07 Mission Therapeutics Ltd Novel compounds
GB202411060D0 (en) 2024-07-29 2024-09-11 Mission Therapeutics Ltd Novel compounds
GB202500610D0 (en) 2025-01-16 2025-03-05 Mission Therapeutics Ltd Novel compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036168A2 (en) * 2006-08-30 2008-03-27 The Regents Of The University Of Michigan New small molecule inhibitors of mdm2 and the uses thereof
WO2009026197A1 (en) * 2007-08-20 2009-02-26 Glaxo Group Limited Novel cathepsin c inhibitors and their use
US20120264738A1 (en) * 2011-03-10 2012-10-18 Yuuichi Sugimoto Dispiropyrrolidine derivatives
RU2571100C2 (ru) * 2009-12-02 2015-12-20 Ф. Хоффманн-Ля Рош Аг Спироиндолинонпирролидины, полезные при лечении злокачественных новообразований

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530384A (ja) 2000-04-06 2003-10-14 メルク フロスト カナダ アンド カンパニー カテプシンシステインプロテアーゼ阻害薬
US7759383B2 (en) 2005-02-22 2010-07-20 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
WO2008144507A2 (en) 2007-05-16 2008-11-27 President And Fellows Of Harvard College Spirooxindole inhibitors of aurora kinase
GB0922589D0 (en) 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
EP2752191A1 (en) 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
LT3277677T (lt) 2015-03-30 2021-05-25 Mission Therapeutics Limited 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai
EP3322702B1 (en) 2015-07-14 2019-11-20 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) * 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
MA43753A (fr) 2016-03-24 2018-11-28 Mission Therapeutics Ltd Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu
ES2850349T3 (es) 2016-09-27 2021-08-27 Mission Therapeutics Ltd Derivados de cianopirrolidina con actividad como inhibidores de USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036168A2 (en) * 2006-08-30 2008-03-27 The Regents Of The University Of Michigan New small molecule inhibitors of mdm2 and the uses thereof
WO2009026197A1 (en) * 2007-08-20 2009-02-26 Glaxo Group Limited Novel cathepsin c inhibitors and their use
RU2571100C2 (ru) * 2009-12-02 2015-12-20 Ф. Хоффманн-Ля Рош Аг Спироиндолинонпирролидины, полезные при лечении злокачественных новообразований
US20120264738A1 (en) * 2011-03-10 2012-10-18 Yuuichi Sugimoto Dispiropyrrolidine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHIMRT O. et al, Targeting Deubiquitinases Enabled by Chemical Synthesis of Proteins, JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2012, vol.134, no.6, p.3281-3289. *

Also Published As

Publication number Publication date
RU2018133279A (ru) 2020-04-06
EP3423454B1 (en) 2022-05-25
SG11201807301SA (en) 2018-09-27
JP6959247B2 (ja) 2021-11-02
MY196836A (en) 2023-05-03
HK1258589A1 (zh) 2019-11-15
BR112018017086A2 (pt) 2019-01-02
CA3016370C (en) 2023-08-01
JP2019507177A (ja) 2019-03-14
AU2017225371A1 (en) 2018-10-11
US20190048008A1 (en) 2019-02-14
NZ746531A (en) 2022-03-25
MA43701A (fr) 2018-11-28
CO2018009275A2 (es) 2018-10-10
WO2017149313A1 (en) 2017-09-08
KR20180119644A (ko) 2018-11-02
AU2017225371B2 (en) 2020-07-02
ZA201803910B (en) 2020-01-29
CN108602823A (zh) 2018-09-28
GB201603779D0 (en) 2016-04-20
BR112018017086B1 (pt) 2024-02-20
IL261552B (en) 2021-03-25
EP3423454A1 (en) 2019-01-09
US20220106315A1 (en) 2022-04-07
IL261552A (en) 2018-10-31
US10654853B2 (en) 2020-05-19
CA3016370A1 (en) 2017-09-08
US20200247803A1 (en) 2020-08-06
MX382562B (es) 2025-03-13
ES2919549T3 (es) 2022-07-27
KR102384139B1 (ko) 2022-04-07
JP2021193144A (ja) 2021-12-23
RU2018133279A3 (cg-RX-API-DMAC7.html) 2020-04-06
US11236092B2 (en) 2022-02-01
JP7280928B2 (ja) 2023-05-24
CN108602823B (zh) 2022-04-01
EP4067355A1 (en) 2022-10-05

Similar Documents

Publication Publication Date Title
JP7280928B2 (ja) 脱ユビキチン化酵素(dub)阻害剤としてのスピロ縮合ピロリジン誘導体
CN113557235B (zh) 用于药物治疗的杂环化合物
US10640498B2 (en) Compounds
JP7084918B2 (ja) Usp30の阻害剤としての活性を有するシアノピロリジン誘導体
RU2734256C2 (ru) Новые соединения
JP6810148B2 (ja) Dubの阻害剤としてのシアノピロリジン誘導体
US20120202804A1 (en) Fused aminodihydro-oxazine derivatives
WO2015200677A2 (en) Prmt5 inhibitors and uses thereof
JP2016537366A (ja) カゼインキナーゼ1d/e阻害剤としての置換された4,5,6,7−テトラヒドロピラゾロ[1,5−a]ピラジン誘導体
WO2018137618A1 (en) Compounds for inhibiting lrrk2 kinase activity
US20240034731A1 (en) Aza-quinazoline compounds and methods of use
HK1258589B (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
NZ746531B2 (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
US20250235456A1 (en) Methods of use for aza-quinazoline compounds